Research

Thank you to those of you who have already responded to this research request. There is still time to get involved. We have been approached by researchers from the Royal Holloway University. They are looking into the social networks, relationships and health and wellbeing of people with MS to better understand the ways that the […]

We have been approached by researchers from the Royal Holloway University. They are looking into the social networks, relationships and health and wellbeing of people with MS to better understand the ways that the illness progresses and they are looking for some of our members to take part in their research. What’s involved? The researchers

A new study has shown that diets which are high in fish and fish oils may have a role to play in slowing MS progression.  A team of researchers investigated the influence of fish consumption on disability progression in MS. They showed that people that ate fish regularly experienced reduced MS progression. This result may

We have been contacted by Emily White, a PhD student, who is looking for people with MS to complete a 30 minute survey. Please help out if you can. “My name is Emily, and I am a PhD student at King’s College London, funded by the MS Society. I am currently developing an unguided intervention

REFUEL-MS is an exciting 5.5-year research programme at King’s College London. Funded by the MS Society and National Institute for Health and Care Research (NIHR). REFUEL-MS focuses on tackling fatigue, a debilitating and often invisible symptom that affects over 90% of people living with MS. The team has developed an app-based digital treatment that combines

This information session with Dr Gretchen Hawley will explore the powerful concepts of neuroplasticity and remyelination – two key factors in managing and slowing the progression of MS. This session will provide practical strategies and the latest research to help you improve movement, enhance strength, and stay informed. Neuroplasticity is the brain’s ability to rewire

Initial results from a clinical trial show that a drug called tolebrutinib can significantly slow down disability progression in people with secondary progressive MS who no longer experience relapses.  The study recruited 1,131 participants with non-relapsing (non-active) secondary progressive MS. Participants were randomised with some taking tolebrutinib and others taking a placebo (a dummy drug) for up to

REFUEL-MS is an exciting research project developing an app-based treatment for MS-related fatigue using cognitive behavioural therapy (CBT), exercise and balance techniques. They have recently previewed the first version of the app. The content has been developed using the latest literature in close collaboration with experts from across the country, as well as those living with

ECTRIMS Patient Community Day is a day for people living with MS and related conditions to learn from top neurological experts about progress and updates being made in the treatment of their conditions. A roundtable panel of MS experts will discuss the latest progress being made in research, treatment and care – with a focus on trending